Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).
Keyword(s):
2009 ◽
Vol 7
(2)
◽
pp. 265
◽
Keyword(s):
Keyword(s):
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. LBA1011-LBA1011
◽
Keyword(s):
2011 ◽
Vol 22
(4)
◽
pp. 412-413
Keyword(s):
2018 ◽
Vol 90
◽
pp. 153-155
◽
Keyword(s):